New York, June 22, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Anti-Hypertensive Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030” – https: //www.reportlinker. com / p06097019 /? utm_source = GNW
The global antihypertensive drug market is expected to grow from $ 24.17 billion in 2020 to $ 24.37 billion in 2021 at a compound annual growth rate (CAGR) of 0.8%. The slow growth is mainly due to the COVID-19 outbreak, as hypertensive drugs have a negative effect on COVID-19 patients. The market is expected to reach $ 27.81 billion in 2025 at a CAGR of 3.4%.
The antihypertensive drug market consists of sales of antihypertensive drugs and related services. These drugs are reused to prevent heart failure, kidney failure, and acute hypertension-induced strokes.
Some of the main antihypertensive drugs include diuretics, angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers.
The market covered in this report is segmented by Therapeutics into Diuretics, Angiotensin Receptor Inhibitors (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, renin inhibitors, vasodilators; by source of disease in primary hypertension, secondary hypertension; by end users in hospitals, clinics, home care.
The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East & Africa.
The low knowledge of antihypertensive drugs among the population is one of the main constraints of the antihypertensive drugs market. First, most people in developing countries neglect their checkups and are unaware of the state of hypertension existing in them. until they detect extreme symptoms Second, people with hypertension do not stick to their treatment schedule and stop taking their medication after 1 to 2 weeks until symptoms return, which is a huge challenge for the antihypertensive drug market.
For example, BMC Research Notes published a research survey (from a developing country) that found that out of a total of 112 hypertensive subjects with stroke, only 17% of them were on antihypertensive drugs. Lack of awareness and low drug adherence are holding back the growth of the antihypertensive drug market.
In recent times, the use of combination therapies has increased compared to monotherapy treatment. Monotherapy is the treatment of hypertension with a single drug, while the use of combinations of drugs (combination therapy) acts on several different hypertensive mechanisms.
When the two drugs with different mechanisms of action are combined, the effect is two to five times greater than with monotherapy. Increasing the dose in monotherapy reduces coronary events by 29% and cerebrovascular events by 40%, while combining two antihypertensive drugs with a different mechanism of action reduces coronary events by 40% and cerebrovascular events by 54%.
Thus, the use of combination therapy offers greater protection to a target organ than increasing the dose of monotherapy. The tendency to use combination therapy is therefore more effective and is also widely accepted.
Sedentary lifestyle is a major driver for the growth of the antihypertensive drugs market. Consumption of junk food, lack of a healthy balanced diet, lack of proper sleep due to irregular shifts have all contributed to the increase in hypertension.
Hypertension is the underlying factor in at least 45% of deaths from heart disease and 51% of deaths from stroke. Once the patient is diagnosed with hypertension, the patients should use the drugs to control the hypertension depending on the severity of the disease. .
This creates a sustainable demand for the product and acts as an important engine for the growth of the market.
The United States Food and Drug Administration (FDA) has published a guide to the development of fixed-combination drugs to treat hypertension. This primarily focuses on the clinical development of two drug combinations of previously approved products.
The US FDA expects to see a reduction in side effects for combinations that include doses below the maximum dose of each drug compared to single drug regimens at their maximum dose. Previous physicians typically started a patient on a single drug and titrated up to a maximum dose before adding additional drugs to their schedule, current guidelines recommend starting patients with two drugs at doses lower than their full doses. .
Therefore, this orientation would allow control of fixed combination drugs.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, United Kingdom and United States.
Read the full report: https://www.reportlinker.com/p06097019/?utm_source=GNW
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.